Stryker Corp <SYK.N>: UBS Assumes Coverage With Buy vs Neutral Rating; Target Price $400 vs $380
SYK•Related News
Esquire Financial Holdings Inc <ESQ.O>: Raymond James Raises Target Price to $140 From $130
ESQ•
Lantern Pharma To Advance EMA-Cleared Phase 1B/2 Trial Of Lp-184 (Zirdafulven) In Biomarker-Selected Advanced Bladder Cancer
LTRN•
Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
KNSA•
GSK-Hansoh Osteosarcoma drug succeeds in Phase III studies
GSK•
Elf Beauty Inc raises target price to $100 from $72
ELF•